These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. An unusual triple-negative breast carcinoma. Shousha S; Peston D; Gojis O; Palmieri C Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156 [No Abstract] [Full Text] [Related]
7. [Neoadjuvant systemic chemotherapy for patients with operable breast cancer]. Zhang B; Zhang Q Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):161-5. PubMed ID: 17649628 [No Abstract] [Full Text] [Related]
8. Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology. Warm M; Kates R; Thomas A; Fischer T; Harbeck N Anticancer Res; 2009 Jul; 29(7):2675-80. PubMed ID: 19596945 [TBL] [Abstract][Full Text] [Related]
9. Problems with the progesterone receptor in practice? Jordan VC; Gelber RD J Clin Oncol; 2007 May; 25(15):1957-9. PubMed ID: 17452674 [No Abstract] [Full Text] [Related]
10. New approaches for triple-negative breast cancer. Oncology (Williston Park); 2012 Oct; 26(10):916, 931, 935. PubMed ID: 23175999 [No Abstract] [Full Text] [Related]
11. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? De Maeyer L; Van Limbergen E; De Nys K; Moerman P; Pochet N; Hendrickx W; Wildiers H; Paridaens R; Smeets A; Christiaens MR; Vergote I; Leunen K; Amant F; Neven P J Clin Oncol; 2008 Jan; 26(2):335-6; author reply 336-8. PubMed ID: 18182677 [No Abstract] [Full Text] [Related]
12. [Degree of manifestation of therapeutic pathomorphosis and the nature of the change in the estrogen and progesterone receptors after the radiation and chemotherapy of breast cancer]. Ermilova VD; Koposova TL; Murav'ëva NI; Kuz'mina ZV Vopr Onkol; 1985; 31(12):69-73. PubMed ID: 4082510 [TBL] [Abstract][Full Text] [Related]
13. Are triple-negative and basal-like breast cancer synonymous? Rakha E; Ellis I; Reis-Filho J Clin Cancer Res; 2008 Jan; 14(2):618; author reply 618-9. PubMed ID: 18223240 [No Abstract] [Full Text] [Related]
14. Triple-negative breast cancer and brain metastases. Sait B; Cinar E; Altundag K Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):84. PubMed ID: 19751969 [No Abstract] [Full Text] [Related]
15. [Tamoxifen induced fluorescence as a marker of hormone receptors: cytological study of fine needle biopsy of malignant breast tumors in treated women]. Mouriquand J; Mouriquand C; Sage JC; Saez S; Jacrot M; Gabelle P C R Seances Acad Sci III; 1981 Dec; 293(15):801-6. PubMed ID: 6804016 [TBL] [Abstract][Full Text] [Related]
16. Response to taxanes in triple negative breast cancer. Bulut N; Kilickap S; Sari E; Altundag K Cancer Chemother Pharmacol; 2008 Dec; 63(1):189. PubMed ID: 18317760 [No Abstract] [Full Text] [Related]
17. Comparison of core needle biopsy and surgical specimens in malignant breast lesions regarding histological features and hormone receptor expression. Abdsaleh S; Wärnberg F; Azavedo E; Lindgren PG; Amini RM Histopathology; 2008 May; 52(6):773-5. PubMed ID: 18393972 [No Abstract] [Full Text] [Related]
18. Hormone receptors in the management of breast cancer. Osborne CK Tex Med; 1984 Nov; 80(11):30-2. PubMed ID: 6515569 [No Abstract] [Full Text] [Related]
19. Pharmacotherapy of triple-negative breast cancer. Arslan C; Dizdar O; Altundag K Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211 [TBL] [Abstract][Full Text] [Related]
20. The importance of estrogen and progesterone receptor in primary breast cancer. Clark GM; McGuire WL; Hubay CA; Pearson OH; Carter AC Prog Clin Biol Res; 1983; 132E():183-90. PubMed ID: 6647468 [No Abstract] [Full Text] [Related] [Next] [New Search]